哮喘与慢阻肺中的支气管舒张剂可逆性:三项大型人群研究结果
基于三项国际人群研究共35 628名≥16岁受试者,比较哮喘、慢阻肺及无气道疾病者支气管舒张剂反应(BDR)的三种流量与三种容量定义。FEV1增加≥12%且200 mL的BDR在哮喘中占17.3%、慢阻肺中占18.4%、无气道疾病者占5.1%。哮喘中BDR与喘息、特应性及呼出气一氧化氮分数升高相关,慢阻肺中BDR与症状负担、急性加重或健康状况无关。
要点
- FEV1增加≥12%且200 mL的BDR在慢阻肺中至少与哮喘一样常见。
- 哮喘中BDR与喘息、特应性及呼出气一氧化氮分数升高相关。
- 慢阻肺中校正舒张前FEV1后BDR与症状、急性加重及健康状况无关。
核心结论
- 支气管舒张剂可逆性在慢阻肺参与者中至少与哮喘一样常见,提示该指标在人群研究中区分哮喘与慢阻肺的价值有限。
- 在哮喘中,支气管舒张剂可逆性可能是一个表型标志物。
研究设计与样本
- 三项大型国际人群研究,共纳入35 628名年龄≥16岁的受试者。
- 受试者分为三组:当前哮喘(n=2833)、慢阻肺(n=1146)和无气道疾病(n=31 649)。
- 测量200 μg沙丁胺醇吸入前及吸入后15分钟的FEV1和FVC。
- 采用三种流量相关可逆性定义(FEV1增加)和三种容量相关可逆性定义(FVC增加)。
主要发现
- FEV1增加≥12%且200 mL的支气管舒张剂可逆性患病率在哮喘中为17.3%,慢阻肺中为18.4%,无气道疾病者中为5.1%。
- 哮喘中,支气管舒张剂可逆性与喘息相关(OR 1.36,95% CI 1.04-1.79)。
- 哮喘中,支气管舒张剂可逆性与特应性相关(OR 1.36,95% CI 1.04-1.79)。
- 哮喘中,支气管舒张剂可逆性与更高的呼出气一氧化氮分数相关。
- 慢阻肺中,校正舒张前FEV1后,流量或容量相关支气管舒张剂可逆性均与症状负担、急性加重或健康状况无关。
关键数值与推荐
- 流量相关可逆性定义之一为FEV1增加≥12%且200 mL。
- 共使用三种流量相关可逆性定义和三种容量相关可逆性定义。
临床怎么用
- 在人群中以支气管舒张剂可逆性区分哮喘与慢阻肺价值有限,需结合其他临床特征。
- 哮喘患者若存在支气管舒张剂可逆性,可考虑作为表型标志物参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway diseases. The aim of this investigation was to compare different methods for measuring BDR in participants with asthma and chronic obstructive pulmonary disease (COPD) and to study to the extent to which BDR was related to symptom burden and phenotypic characteristics.Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were measured before and 15 min after 200 μg of salbutamol in 35 628 subjects aged ≥16 years from three large international population studies. The subjects were categorised in three groups: current asthma (n=2833), COPD (n=1146) and no airway disease (n=31 649). Three definitions for flow-related reversibility (increase in FEV1) and three for volume-related reversibility (increase in FVC) were used.The prevalence of bronchodilator reversibility expressed as increase FEV1 ≥12% and 200 mL was 17.3% and 18.4% in participants with asthma and COPD, respectively, while the corresponding prevalence was 5.1% in those with no airway disease. In asthma, bronchodilator reversibility was associated with wheeze (OR 1.36, 95% CI 1.04-1.79), atopy (OR 1.36, 95% CI 1.04-1.79) and higher exhaled nitric oxide fraction, while in COPD neither flow- nor volume-related bronchodilator reversibility was associated with symptom burden, exacerbations or health status after adjusting for pre-bronchodilator FEV1Bronchodilator reversibility was at least as common in participants with COPD as those with asthma. This indicates that measures of reversibility are of limited value for distinguishing asthma from COPD in population studies. However, in asthma, bronchodilator reversibility may be a phenotypic marker.
引用
- Janson C, Malinovschi A, Amaral AFS, et al. Bronchodilator reversibility in asthma and COPD: findings from three large population studies. Eur Respir J. 2019. PMID: 31221806. doi:10.1183/13993003.00561-2019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。